Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김휘영 | * |
dc.date.accessioned | 2018-11-21T16:30:17Z | - |
dc.date.available | 2018-11-21T16:30:17Z | - |
dc.date.issued | 2018 | * |
dc.identifier.issn | 2045-2322 | * |
dc.identifier.other | OAK-23041 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/246695 | - |
dc.description.abstract | Whether a sustained virological response (SVR) improves long-term outcomes in chronic hepatitis C patients with earlier-stage fibrosis has not been established. We investigated the differential effect of SVR on the risk of outcomes according to hepatic fibrosis grade. Fibrosis grade was categorised using FIB-4: <1.45, low-probability of significant fibrosis; 1.45–3.25, intermediate-probability; and ≥3.25, high-probability. Primary and secondary endpoints were hepatocellular carcinoma (HCC) occurrence and death, respectively. Among 1,373 included chronic hepatitis C patients, 744 patients were treated with interferon-based or –free regimens and 622 (83.6%) achieved SVR. SVR was independently associated with lower risk of HCC (vs. untreated: adjusted hazard ratio [aHR], 0.165; 95% confidence interval [CI], 0.077–0.350; P < 0.001) and overall death (vs. untreated; aHR, 0.146; 95% CI, 0.050–0.424; P < 0.001) during the median observation of 3.5 (interquartile range, 1.9–6.6) years. The SVR group had significantly lower risk of HCC than the untreated group among patients with intermediate-probability (n = 492: aHR, 0.171; 95% CI, 0.051–0.578; P = 0.004) and high-probability (n = 446: aHR, 0.243; 95% CI, 0.107–0.551; P < 0.001) of significant fibrosis. HRs were maintained after balancing with inverse probability weighting. SVR was associated with reduced risk of HCC development and all-cause mortality in patients with chronic hepatitis C. © 2018, The Author(s). | * |
dc.language | English | * |
dc.publisher | Nature Publishing Group | * |
dc.title | Differential Effect of HCV Eradication and Fibrosis Grade on Hepatocellular Carcinoma and All-cause Mortality | * |
dc.type | Article | * |
dc.relation.issue | 1 | * |
dc.relation.volume | 8 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.journaltitle | Scientific Reports | * |
dc.identifier.doi | 10.1038/s41598-018-31839-y | * |
dc.identifier.wosid | WOS:000444374900002 | * |
dc.identifier.scopusid | 2-s2.0-85053277085 | * |
dc.author.google | Bin Lee Y. | * |
dc.author.google | Nam J.Y. | * |
dc.author.google | Lee J.-H. | * |
dc.author.google | Chang Y. | * |
dc.author.google | Cho H. | * |
dc.author.google | Cho Y.Y. | * |
dc.author.google | Cho E.J. | * |
dc.author.google | Yu S.J. | * |
dc.author.google | Kim H.Y. | * |
dc.author.google | Lee D.H. | * |
dc.author.google | Lee J.M. | * |
dc.author.google | Hwang S.G. | * |
dc.author.google | Kim Y.J. | * |
dc.author.google | Yoon J.-H. | * |
dc.contributor.scopusid | 김휘영(56493773500) | * |
dc.date.modifydate | 20240429140130 | * |